Intensity Therapeutics (NASDAQ:INTS) and Mydecine Innovations Group (OTCMKTS:MYCOF) Head to Head Comparison

Mydecine Innovations Group (OTCMKTS:MYCOF) and Intensity Therapeutics (NASDAQ:INTS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Mydecine Innovations Group and Intensity Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mydecine Innovations Group	N/A	N/A	N/A
Intensity Therapeutics	N/A	-116.61%	-94.01%

Valuation & Earnings

This table compares Mydecine Innovations Group and Intensity Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mydecine Innovations Group	N/A	N/A	N/A	N/A	N/A
Intensity Therapeutics	N/A	N/A	-$11.61 million	($5.71)	-0.69

Analyst Recommendations

This is a summary of current ratings and recommmendations for Mydecine Innovations Group and Intensity Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mydecine Innovations Group	0	0	0	0	0.00
Intensity Therapeutics	1	0	2	1	2.75

Intensity Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 846.97%. Given Intensity Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Intensity Therapeutics is more favorable than Mydecine Innovations Group.

Institutional & Insider Ownership

3.7% of Intensity Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Intensity Therapeutics beats Mydecine Innovations Group on 6 of the 8 factors compared between the two stocks.

About Mydecine Innovations Group

Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

About Intensity Therapeutics

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.